BR9811923A - Compostos possuindo atividade neuronal - Google Patents
Compostos possuindo atividade neuronalInfo
- Publication number
- BR9811923A BR9811923A BR9811923-0A BR9811923A BR9811923A BR 9811923 A BR9811923 A BR 9811923A BR 9811923 A BR9811923 A BR 9811923A BR 9811923 A BR9811923 A BR 9811923A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- neuronal activity
- methods
- development
- nerve
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 230000001537 neural effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108010025020 Nerve Growth Factor Proteins 0.000 abstract 1
- 102000007072 Nerve Growth Factors Human genes 0.000 abstract 1
- 230000018109 developmental process Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000030363 nerve development Effects 0.000 abstract 1
- 210000002241 neurite Anatomy 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 230000003961 neuronal insult Effects 0.000 abstract 1
- 239000003900 neurotrophic factor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92083897A | 1997-08-29 | 1997-08-29 | |
| US09/085,441 US6268384B1 (en) | 1997-08-29 | 1998-05-27 | Compounds possessing neuronal activity |
| PCT/US1998/017816 WO1999010340A1 (en) | 1997-08-29 | 1998-08-27 | Compounds possessing neuronal activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9811923A true BR9811923A (pt) | 2000-08-15 |
Family
ID=26772724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9811923-0A BR9811923A (pt) | 1997-08-29 | 1998-08-27 | Compostos possuindo atividade neuronal |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7109215B2 (enExample) |
| EP (1) | EP1007521A1 (enExample) |
| JP (1) | JP2001514177A (enExample) |
| CN (1) | CN100436447C (enExample) |
| AU (1) | AU766579B2 (enExample) |
| BR (1) | BR9811923A (enExample) |
| CA (1) | CA2300134A1 (enExample) |
| ID (1) | ID23675A (enExample) |
| IL (1) | IL134536A0 (enExample) |
| IN (1) | IN191127B (enExample) |
| IS (1) | IS5379A (enExample) |
| NO (1) | NO321790B1 (enExample) |
| NZ (1) | NZ502820A (enExample) |
| PL (1) | PL195273B1 (enExample) |
| SG (1) | SG129998A1 (enExample) |
| TW (1) | TW570919B (enExample) |
| WO (1) | WO1999010340A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6514686B2 (en) | 1997-04-28 | 2003-02-04 | The University Of British Columbia | Method and composition for modulating amyloidosis |
| AU1708099A (en) | 1998-06-03 | 1999-12-20 | Amgen, Inc. | N-linked sulfonamides of n-heterocyclic carboxylic acids or carboxylic acid isosteres |
| US6331537B1 (en) | 1998-06-03 | 2001-12-18 | Gpi Nil Holdings, Inc. | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds |
| US6339101B1 (en) * | 1998-08-14 | 2002-01-15 | Gpi Nil Holdings, Inc. | N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders |
| US6333340B1 (en) * | 1998-08-14 | 2001-12-25 | Gpi Nil Holdings, Inc. | Small molecule sulfonamides for vision and memory disorders |
| US6300341B1 (en) * | 1998-09-30 | 2001-10-09 | The Procter & Gamble Co. | 2-substituted heterocyclic sulfonamides |
| WO2001002362A1 (en) * | 1999-07-06 | 2001-01-11 | Vertex Pharmaceuticals Incorporated | Azo amino acid derivatives for the treatment of neurological diseases |
| AU5912800A (en) * | 1999-07-06 | 2001-01-22 | Vertex Pharmaceuticals Incorporated | Beta-amino acid derivatives for the treatment of neurological diseases |
| JP2003503480A (ja) * | 1999-07-06 | 2003-01-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | ニューロン活性を有するｎ−ヘテロ環誘導体 |
| AU6497200A (en) * | 1999-07-30 | 2001-02-19 | Vertex Pharmaceuticals Incorporated | Acyclic and cyclic amine derivatives |
| EP1202970A1 (en) * | 1999-07-30 | 2002-05-08 | Vertex Pharmaceuticals Incorporated | Cyclic amine derivatives for the treatment of neurological diseases |
| JP2003507376A (ja) * | 1999-08-18 | 2003-02-25 | シエーリング アクチエンゲゼルシャフト | 神経活性を示すピペリジンおよびピロリジン誘導体 |
| US7253169B2 (en) | 1999-11-12 | 2007-08-07 | Gliamed, Inc. | Aza compounds, pharmaceutical compositions and methods of use |
| US6818643B1 (en) | 1999-12-08 | 2004-11-16 | Bristol-Myers Squibb Company | Neurotrophic bicyclic diamides |
| AU1464101A (en) | 1999-12-21 | 2001-07-03 | Gpi Nil Holdings, Inc. | Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same |
| JP2002068973A (ja) * | 2000-06-16 | 2002-03-08 | Meiji Milk Prod Co Ltd | 幹細胞分化誘導促進剤 |
| US6693099B2 (en) | 2000-10-17 | 2004-02-17 | The Procter & Gamble Company | Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance |
| US6376514B1 (en) | 2000-10-17 | 2002-04-23 | The Procter & Gamble Co. | Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof |
| PL376149A1 (en) * | 2002-10-03 | 2005-12-27 | Vertex Pharmaceuticals Incorporated | Piperazine and piperidine derivatives for treatment of neurological diseases |
| WO2005033068A1 (en) * | 2003-10-06 | 2005-04-14 | Oy Juvantia Pharma Ltd | Somatostatin receptor 1 and/or 4 selective agonists and antagonists |
| JP2007523196A (ja) * | 2004-02-20 | 2007-08-16 | ライナット ニューロサイエンス コーポレイション | Ｎｔ−４／５を用いて肥満または糖尿病を処置する方法 |
| US7935342B2 (en) * | 2006-02-02 | 2011-05-03 | Rinat Neuroscience Corp. | Methods for treating obesity by administering a trkB antagonist |
| EP1988923A1 (en) * | 2006-02-02 | 2008-11-12 | Rinat Neuroscience Corp. | Methods for treating unwanted weight loss or eating disorders by administering a trkb agonist |
| BRPI0720473A2 (pt) * | 2006-12-20 | 2014-01-14 | Rinat Neuroscience Corp | Agonistas de trkb para tratamento de distúbios autoimunes |
| US9152929B2 (en) | 2013-01-23 | 2015-10-06 | Splunk Inc. | Real time display of statistics and values for selected regular expressions |
| TWI744300B (zh) * | 2016-03-23 | 2021-11-01 | 里爾中央醫學中心 | 改良性熱處理的血小板顆粒裂解液在製備用於治療神經系統疾病的組合物的用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4792555A (en) * | 1987-03-20 | 1988-12-20 | American Home Products Corporation | Phospholipase A2 inhibitors |
| MX9202466A (es) * | 1991-05-24 | 1994-06-30 | Vertex Pharma | Compuestos inmunosupresores novedosos. |
| NZ314207A (en) * | 1992-09-28 | 2000-12-22 | Vertex Pharma | 1-(2-Oxoacetyl)-piperidine-2-carboxylic acid derivatives as multi drug resistant cancer cell sensitizers |
| US5686469A (en) * | 1993-02-09 | 1997-11-11 | Miles Inc. | Aminomethylene derivaties as immunosuppressants |
| US5744485A (en) * | 1994-03-25 | 1998-04-28 | Vertex Pharmaceuticals Incorporated | Carbamates and ureas as modifiers of multi-drug resistance |
| US5721256A (en) * | 1997-02-12 | 1998-02-24 | Gpi Nil Holdings, Inc. | Method of using neurotrophic sulfonamide compounds |
-
1998
- 1998-08-27 WO PCT/US1998/017816 patent/WO1999010340A1/en not_active Ceased
- 1998-08-27 EP EP98941093A patent/EP1007521A1/en not_active Withdrawn
- 1998-08-27 SG SG200201262-3A patent/SG129998A1/en unknown
- 1998-08-27 JP JP2000507669A patent/JP2001514177A/ja not_active Withdrawn
- 1998-08-27 AU AU89236/98A patent/AU766579B2/en not_active Ceased
- 1998-08-27 CA CA002300134A patent/CA2300134A1/en not_active Abandoned
- 1998-08-27 NZ NZ502820A patent/NZ502820A/xx unknown
- 1998-08-27 CN CNB988093553A patent/CN100436447C/zh not_active Expired - Fee Related
- 1998-08-27 ID IDW20000402A patent/ID23675A/id unknown
- 1998-08-27 BR BR9811923-0A patent/BR9811923A/pt not_active IP Right Cessation
- 1998-08-27 PL PL98338791A patent/PL195273B1/pl not_active IP Right Cessation
- 1998-08-27 IL IL13453698A patent/IL134536A0/xx active IP Right Grant
- 1998-08-28 TW TW087114310A patent/TW570919B/zh not_active IP Right Cessation
-
2000
- 2000-02-18 IS IS5379A patent/IS5379A/is unknown
- 2000-02-25 NO NO20000953A patent/NO321790B1/no not_active IP Right Cessation
- 2000-06-26 IN IN362CA2000 patent/IN191127B/en unknown
-
2001
- 2001-06-27 US US09/815,193 patent/US7109215B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| SG129998A1 (en) | 2007-03-20 |
| IS5379A (is) | 2000-02-18 |
| NO20000953D0 (no) | 2000-02-25 |
| PL195273B1 (pl) | 2007-08-31 |
| NO321790B1 (no) | 2006-07-03 |
| US20020013351A1 (en) | 2002-01-31 |
| TW570919B (en) | 2004-01-11 |
| AU8923698A (en) | 1999-03-16 |
| EP1007521A1 (en) | 2000-06-14 |
| IL134536A0 (en) | 2001-04-30 |
| IN191127B (enExample) | 2003-09-27 |
| PL338791A1 (en) | 2000-11-20 |
| AU766579B2 (en) | 2003-10-16 |
| JP2001514177A (ja) | 2001-09-11 |
| CA2300134A1 (en) | 1999-03-04 |
| ID23675A (id) | 2000-05-11 |
| CN100436447C (zh) | 2008-11-26 |
| CN1271354A (zh) | 2000-10-25 |
| US7109215B2 (en) | 2006-09-19 |
| NO20000953L (no) | 2000-05-02 |
| NZ502820A (en) | 2002-10-25 |
| WO1999010340A1 (en) | 1999-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9811923A (pt) | Compostos possuindo atividade neuronal | |
| BRPI9815772A (pt) | emprego de hidrogeno fumaratos de alquila para tratamento de psoríase, artrite psoriática, neurodermatites e enterite regional de crohn | |
| BR9609333A (pt) | Processos e composições para estimular crescimento de neurite | |
| AR015105A1 (es) | Una composicion que comprende derivados de urea o carbonato y factores neurotroficos para estimular el crecimiento de neuritas en celulas nerviosas y unmedicamento que la comprende | |
| BRPI0411319A (pt) | compostos terapeuticamente ativos e sua utilização | |
| BRPI0413582A (pt) | compostos, composições e métodos para inibir a atividade de proteasome | |
| BR9713465A (pt) | Inibidores metalotprotease de amina cìclica sibstituìda | |
| AU3311095A (en) | Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use | |
| BR9806870A (pt) | Composto, processo para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, formulação farmacêutica, e, uso de um composto e processo para preparar o mesmo. | |
| DE60037578D1 (de) | Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen | |
| BR9907233A (pt) | Polìmeros inibidores de lipase e seu uso | |
| BRPI0408523A (pt) | métodos para melhorar um sintoma de esclerose múltipla em um indivìduo, para melhorar esclerose múltipla em um indivìduo mamìfero, para modular uma deficiência de il-10, ou um distúrbio associado com uma deficiência de il-10 em um indivìduo mamìfero, para tratar ou prevenir um distúrbio imunológico em um indivìduo mamìfero e para avaliar o tratamento de esclerose múltipla em um indivìduo mamìfero, composição farmacêutica, e, artigo de manufatura | |
| BR0215622A (pt) | Inibidores da dpiv com base em glutaminila | |
| BR9808109A (pt) | Inibidor terapêutico de células vasculares da musculatura lisa | |
| AP9901518A0 (en) | Methods and compositions for stimulating neurite growth using compounds with affinity for FKBP12 in combination with neurotrophic factors. | |
| BRPI0516437A (pt) | utilização de uma quantidade eficaz de pelo menos um microorganismo, processo de tratamento cosmético, composição cosmética e/ou dermatológica e composição para absorção oral | |
| BRPI0411295A (pt) | compostos e seu uso na terapia | |
| BR0016150A (pt) | Compostos, composições e métodos para estìmulo de crescimento e alongamento neuronal | |
| BR0309127A (pt) | Composição para proliferação de células | |
| BR9813391A (pt) | Composição de epo, preparado farmacêutico e processos para produzir uma composição de epo e para aumentar a atividade especìfica de uma composição de epo | |
| BRPI0408834A (pt) | composições tópicas de l-carnitina | |
| BRPI0519148A2 (pt) | inibidores de homodimerizaÇço de myd88 | |
| BR0317395A (pt) | Sìlica estruturalmente modificada | |
| AU2101800A (en) | Skin protection agents containing a fragment mixture produced from hyaluronic acid by hydrolysis | |
| BR9916323A (pt) | Inibidores da integrina alfavbeta6 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 12A E 13A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 12A, 13A E 14A ANUIDADES. |